




OPPORTUNITY

ALLOZYNE, a privately held and clinical stage biotech, has rapidly developed a number of protein therapeutics through its next generation protein engineering technology in order to serve unmet medical need in various autoimmune and CNS diseases. These platforms, **CAESAR** and **VIGENÈRE**, are able to site specifically modify any protein sequence through the substitution or addition of non-canonical amino acids, which possess unique chemical functions, create the opportunity to site specifically modify proteins through various conjugations that will lead to enhanced efficacy, safety and tolerability profile. Engineering proteins in this manner unlocks an advanced class of chemical reactions that are superior to conventional methods available for protein modification.


BIOCIPHERING PLATFORMS PROVIDE HANDLES FOR SITE SPECIFIC PROTEIN MODIFICATION



CAESAR Proteins are synthesized in cells that are unable to provide one of the 20 amino acids necessary for survival. Instead of the missing amino acid an analog is supplemented to the cells. In such conditions the cells generate novel proteins with amino acid analogs incorporated in place of its natural counterpart and used as specific sites for subsequent chemical modifications and improvement of polypeptide features.

VIGENÈRE Proteins are synthesized in cells expressing a mutant synthetase-tRNA that incorporates an added 21st amino acid analog. No alteration to the wild type sequence is needed on the target protein. The amino acid analog is used as the site for chemical modifications in order to improve a selected feature of the polypeptide.

AZ01, AZ17 and AZ05 EXEMPLIFY BROAD APPLICATION OF BOTH BIOCIPHERING PLATFORMS



Company Snapshot

Proprietary site specific protein bioconjugation platform

Autoimmunity and MS focused clinical stage pipeline

Founded in 2005 by MPM, ARCH and OVP

Privately held and Seattle based

\$43M in funding to date

Exclusive rights from California Institute of Technology

World renowned Scientific Advisory Board

Management Team

Meenu Chhabra
President & CEO

John Bencich
Chief Financial Officer

Kenneth Grabstein, Ph.D.
Chief Scientific Officer

Board of Directors

Michael Steinmetz, Ph.D.
Executive Chairman
Managing Director of Clarus Ventures / MPM BV III

Carl Weissman
Managing Director
OVP


Steven Gillis, Ph.D.
Managing Director
ARCH Venture Partners

David A. Tirrell, Ph.D.,
Chair of Chemistry and Chemical Engineering Departments
CALTECH


Meenu Chhabra,
President & CEO
ALLOZYNE

AZ01: LONG ACTING INTERFERON β IN PHASE I

AZ01 is a long acting form of interferon β , the current gold standard therapy for multiple sclerosis patients and represents the lead product candidate in **ALLOZYNE's** risk-reward balanced MS pipeline. Construction with the *E. coli* based, **CAESAR** platform allows for customization of the position, size and architecture of the conjugated polyethylene glycol (PEG) moiety, resulting in an improved half-life compared to commercially available interferon β molecules. Clinical and preclinical data supports every-other-week with the possibility of monthly dosing, as well as fewer side effects and likely improvement in patient compliance.




AZ17: BISPECIFIC MOLECULE WITH BROAD THERAPEUTIC APPLICATIONS FOR INFLAMMATORY DISEASES IN PC DEVELOPMENT



Th17 cells have been recently linked to the disease progression of MS as well as have been shown to play a role in other autoimmune diseases such as Crohn's and psoriasis. **AZ17**, a bispecific molecule generated from *E. coli*, simultaneously inhibits two cytokines involved in the Th17 pathway through a novel mechanism of action. The site specific linkage of **AZ17's** two binding domains is a product of **ALLOZYNE's** proprietary **CAESAR** bioconjugation platform. **AZ17** has demonstrated superior efficacy to that of a marketed product in a human disease model and has shown to inhibit the differentiation and effector function of human Th17 cells in vivo.

AZ05: ANTIBODY-DRUG CONJUGATE (ADC) TO TREAT UNDISCLOSED INDICATIONS IN ONCOLOGY



ALLOZYNE has developed a platform for the introduction of non natural amino acids (NNAAs) into proteins expressed in the mammalian expression systems that are required for producing monoclonal antibodies. This method is proprietary to **ALLOZYNE** and involves the engineering of the manufacturing cell line to deliver the NNAAs at any specific position that enables efficient and effective drug conjugation. The chemical conjugation of highly potent cytotoxic drugs to monoclonal antibodies (ADC) has proven to be an effective means of targeted delivery of drugs, to cancer cells, that would otherwise be too toxic for systemic administration. **ALLOZYNE** has also developed special chemical conjugation chemistries that provide a highly stable linker that is perfectly suited for use in ADCs. The ability to conjugate a toxin that can be readily positioned at favorable sites in the antibody allows full function of the antibody and effective delivery of the toxin.

2011 PIPELINE

Program	Indication	Discovery	Preclinical	Phase I	Phase II	Phase III
AZ01	Multiple Sclerosis					
AZ17	Crohn's Disease					
AZ05	Oncology					

Multiple Sclerosis Advisory Board

Alexander Giaquinto, Ph.D.
Schering Plough Inc.

Douglas Goodin, M.D.
University of California San Francisco

David A. Hafler, M.D.
Harvard Medical School

William Jusko, Ph.D.
University at Buffalo

Ludwig Kappos, M.D.
University Hospital, Basel

Bruce Leuchter, M.D.
Weill Cornell Medical College

Fred Lublin, M.D.
Mt. Sinai Medical Center

Sylvia Lucas, M.D., Ph.D.
University of Washington

Elliot Stupak, Ph.D.
Schering Plough

Biociphering Advisory Board

William Goddard, Ph.D.,
CALTECH

Leroy Hood, Ph.D.,
ISB

Harvey F. Lodish, Ph.D.,
MIT

K. Barry Sharpless, Ph.D.,
SCRIPPS

David A. Tirrell, Ph.D.,
CALTECH

Contact

ALLOZYNE
1600 Fairview Ave E., Suite 300
Seattle, WA 98102
P 206.518.5700
F 206.518.5799
E info@alloyzine.com
W www.alloyzine.com